Gregory K Robbins

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Efficacy of a clinical decision-support system in an HIV practice: a randomized trial
    Gregory K Robbins
    Massachusetts General Hospital, Division of Infectious Diseases, 55 Fruit Street, Cox 5, Boston, MA 02114, USA
    Ann Intern Med 157:757-66. 2012
  2. ncbi request reprint Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection
    Robert W Shafer
    Stanford University Medical Center, Stanford, Calif, USA
    N Engl J Med 349:2304-15. 2003
  3. pmc Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384
    Gregory K Robbins
    Infectious Diseases Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Infect Dis 48:350-61. 2009
  4. pmc Predictors of antiretroviral treatment failure in an urban HIV clinic
    Gregory K Robbins
    Division of Infectious Diseases, Massachusetts General Hospital, Harvard Center for AIDS Research CFAR, and Harvard Medical School, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 44:30-7. 2007
  5. ncbi request reprint Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
    Gregory K Robbins
    Harvard Medical School, Boston, USA
    N Engl J Med 349:2293-303. 2003
  6. pmc Predicting virologic failure in an HIV clinic
    Gregory K Robbins
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 50:779-86. 2010
  7. ncbi request reprint Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    J Acquir Immune Defic Syndr 45:508-14. 2007
  8. ncbi request reprint Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    Clin Infect Dis 45:120-6. 2007
  9. doi request reprint Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy
    Todd Hulgan
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    J Infect Dis 197:858-66. 2008
  10. pmc Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection
    Arthur Y Kim
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 3:e492. 2006

Research Grants

  1. Bridging the Gap HIV Trials and Clinical Practice
    Gregory Robbins; Fiscal Year: 2007

Detail Information

Publications54

  1. pmc Efficacy of a clinical decision-support system in an HIV practice: a randomized trial
    Gregory K Robbins
    Massachusetts General Hospital, Division of Infectious Diseases, 55 Fruit Street, Cox 5, Boston, MA 02114, USA
    Ann Intern Med 157:757-66. 2012
    ..Data to support improved patient outcomes from clinical decision-support systems (CDSSs) are lacking in HIV care...
  2. ncbi request reprint Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection
    Robert W Shafer
    Stanford University Medical Center, Stanford, Calif, USA
    N Engl J Med 349:2304-15. 2003
    ..It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens...
  3. pmc Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384
    Gregory K Robbins
    Infectious Diseases Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Infect Dis 48:350-61. 2009
    ..Whether the baseline CD4 cell count affects reconstitution of immune cell subsets has not been well characterized...
  4. pmc Predictors of antiretroviral treatment failure in an urban HIV clinic
    Gregory K Robbins
    Division of Infectious Diseases, Massachusetts General Hospital, Harvard Center for AIDS Research CFAR, and Harvard Medical School, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 44:30-7. 2007
    ..Predictors of antiretroviral treatment (ART) failure are not well characterized for heterogeneous clinic populations...
  5. ncbi request reprint Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
    Gregory K Robbins
    Harvard Medical School, Boston, USA
    N Engl J Med 349:2293-303. 2003
    ..The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies...
  6. pmc Predicting virologic failure in an HIV clinic
    Gregory K Robbins
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 50:779-86. 2010
    ..We sought to use data captured in the electronic health record (EHR) to develop and validate a prediction rule for virologic failure among patients being treated for infection with human immunodeficiency virus (HIV)...
  7. ncbi request reprint Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    J Acquir Immune Defic Syndr 45:508-14. 2007
    ..Long-term regional body fat outcomes have not been well described in randomized antiretroviral drug trials...
  8. ncbi request reprint Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    Clin Infect Dis 45:120-6. 2007
    ..The effects of initiation of different antiretroviral regimens on testosterone levels and changes in fat-free mass have not been reported...
  9. doi request reprint Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy
    Todd Hulgan
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    J Infect Dis 197:858-66. 2008
    ..Mitochondrial haplogroups and hemochromatosis gene (HFE) polymorphisms have been associated with ART-induced neuropathy. We assessed relationships between these variants and lipoatrophy...
  10. pmc Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection
    Arthur Y Kim
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 3:e492. 2006
    ..Here we examined the effect of a lymphotropic virus, HIV-1, on the ability of coinfected patients to maintain spontaneous control of HCV infection...
  11. ncbi request reprint Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection
    Sigall Kassutto
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 42:1024-31. 2006
    ..Potential predictors of time to virological suppression and CD4+ cell count at > or =12 months were assessed...
  12. pmc Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection
    Marylyn M Addo
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School Division of AIDS, Boston, Massachusetts, United States of America
    PLoS ONE 2:e321. 2007
    ..Recent data suggest that impaired maturation, as defined by the lineage markers CD45RA and CCR7, may contribute to a lack of immune control by these responses...
  13. doi request reprint Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers
    Kathleen E Corey
    Harvard Medical School, Boston, MA, USA
    Infect Control Hosp Epidemiol 30:1000-5. 2009
    ..We sought to determine the safety, tolerability, and acceptance of postexposure prophylaxis with peginterferon alfa-2b in healthcare workers (HCWs) exposed to blood from HCV-infected patients...
  14. ncbi request reprint Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384
    Rajesh T Gandhi
    Massachusetts General Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 42:426-34. 2006
    ..To assess the effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy (ART)...
  15. pmc Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects
    Gail Skowron
    Division of Infectious Diseases, Roger Williams Medical Center, Providence, RI 02908, USA
    J Acquir Immune Defic Syndr 50:250-8. 2009
    ..To evaluate the association between baseline (BL) replication capacity (RC) (RCBL) and immunologic/virologic parameters (at BL and after 48 weeks on therapy) in HIV-1-infected subjects initiating antiretroviral therapy...
  16. pmc Ocular syphilis among HIV-infected patients: a systematic analysis of the literature
    Joseph D Tucker
    Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, GRJ 504, Boston 02114, USA
    Sex Transm Infect 87:4-8. 2011
    ..Objective To examine the literature on HIV-infected patients and determine the results of treatment...
  17. ncbi request reprint Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, Indiana, USA
    AIDS 19:1807-18. 2005
    ..To determine if particular components of antiretroviral drug regimens are associated with greater insulin resistance, dyslipidemia, and peripheral lipoatrophy...
  18. ncbi request reprint High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection
    Georg M Lauer
    Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 127:924-36. 2004
    ..Previous studies have largely focused on limited HLA alleles and predefined CD8+ T-cell epitopes, and, thus, comprehensive studies remain to be performed...
  19. ncbi request reprint Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)
    Julie C Servoss
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, 02114, USA
    J Acquir Immune Defic Syndr 43:320-3. 2006
    ..7; P < 0.003). In conclusion, this study identified known and previously unreported risk factors for severe hepatotoxicity that should be considered before the initiation of ART...
  20. pmc Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study
    Heather J Ribaudo
    Statistical Data Analysis Center, Harvard School of Public Health, Harvard University, Boston, MA, USA
    J Infect Dis 202:717-22. 2010
    ..Slow-metabolizer genotypes were associated with increased central nervous system events among white participants and decreased virologic failure among black participants...
  21. pmc Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes
    Arthur Y Kim
    Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, GRB 504, Boston, Massachusetts 02114, USA
    Gastroenterology 140:686-696.e1. 2011
    ..We aimed to determine the correlations between these alleles and natural outcomes of HCV and determine associated key T-cell responses...
  22. pmc Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection
    Cheryl L Day
    Partners AIDS Research Center, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA
    J Virol 76:12584-95. 2002
    ..Moreover, these data provide important parameters for evaluation of candidate HCV vaccines, and provide rationale for immunotherapy in chronic HCV infection...
  23. pmc Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers
    Cheryl L Day
    Howard Hughes Medical Institute, Partners AIDS Research Center, Boston, Massachusetts, USA
    J Clin Invest 112:831-42. 2003
    ..Moreover, they show that rare populations of memory CD4 T cells can be studied ex vivo in human diseases...
  24. pmc Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells
    Mathias Lichterfeld
    Partners AIDS Research Center, Massachusetts General Hospital, 149 13th St, Boston, MA 02129, USA
    J Exp Med 200:701-12. 2004
    ..This identification of a reversible defect in cell-mediated immunity in chronic HIV-1 infection has important implications for immunotherapeutic interventions...
  25. pmc Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1
    Angela Meier
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, USA
    Nat Med 15:955-9. 2009
    ..Modulation of the TLR7 pathway in pDCs may therefore represent a new approach to reduce HIV-1-associated pathology...
  26. pmc The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
    Florencia Pereyra
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology MIT and Harvard, Boston, MA, USA
    Science 330:1551-7. 2010
    ..These results implicate the nature of the HLA-viral peptide interaction as the major factor modulating durable control of HIV infection...
  27. pmc Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication
    J Judy Chang
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Harvard Medical School, Cambridge, MA 02139, USA
    J Infect Dis 208:830-8. 2013
    ....
  28. ncbi request reprint Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization
    Gregory K Robbins
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Division of AIDS Harvard Medical School, Boston, 02114, USA
    AIDS 17:1121-6. 2003
    ..To determine whether therapeutic immunization with a whole inactivated HIV-1 immunogen augments HIV-1-specific T helper cell responses in chronically infected individuals receiving suppressive antiretroviral therapy (ART)...
  29. pmc Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility
    George L Melikian
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA
    Antimicrob Agents Chemother 56:2305-13. 2012
    ....
  30. pmc Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients
    Takara L Stanley
    Massachusetts General Hospital and Harvard Medical School, Boston, 02114, USA
    AIDS 23:1349-57. 2009
    ..To determine the effects of switching from lopinavir/ritonavir (LPV/r) to atazanavir/ritonavir (ATV/r) on muscle glucose uptake, glucose homeostasis, lipids, and body composition...
  31. ncbi request reprint Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    Raymond T Chung
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 351:451-9. 2004
    ..We conducted a multicenter, randomized trial comparing peginterferon plus ribavirin with interferon plus ribavirin for the treatment of chronic hepatitis C in persons coinfected with HIV...
  32. ncbi request reprint Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study
    Todd Hulgan
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    AIDS 19:1341-9. 2005
    ..The objective of this study was to determine if NRTI-associated peripheral neuropathy is associated with European mitochondrial haplogroups...
  33. pmc Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection
    Judith J Lok
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    AIDS 24:1867-76. 2010
    ..We estimated the long-term CD4 cell count trajectory accounting for losses-to-follow-up and treatment discontinuations...
  34. ncbi request reprint Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384
    Gregory K Robbins
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    HIV Clin Trials 14:235-53. 2013
    ..Effective and easy to implement interventions to improve adherence to antiretroviral therapy are needed...
  35. pmc Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing
    George L Melikian
    Department of Medicine, Stanford University, Stanford, CA, USA
    J Antimicrob Chemother 69:12-20. 2014
    ....
  36. pmc Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses
    Georg M Lauer
    Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Virol 76:2817-26. 2002
    ..In addition, they show a consistent and profound impairment in cellular immune responses to HCV compared to HIV-1 in HIV-1-HCV-coinfected persons...
  37. pmc The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial
    Samir K Gupta
    Division of Infectious Diseases, Indiana University School of Medicine, Wishard Hospital, OPW 430, 1001 W 10th Street, Indianapolis, IN 46202, USA
    Nephrol Dial Transplant 20:2237-42. 2005
    ..Alternatively, albuminuria may improve with HAART as a result of treating renal parenchymal HIV infection. Longitudinal studies have not been performed previously addressing the effects of HAART on albuminuria...
  38. ncbi request reprint Reactive Epstein-Barr virus-related polyclonal lymphoproliferative disorder in a patient with AIDS
    Stanley I Martin
    Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Infect Dis 41:e76-9. 2005
    ..We report an analogous case of posttransplantation polyclonal lymphoproliferative disorder in a patient with human immunodeficiency virus infection who was successfully treated with antiretroviral therapy...
  39. pmc Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis
    Heather J Ribaudo
    Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts
    Clin Infect Dis 57:1607-17. 2013
    ..The cause for these disparities is uncertain. We sought to examine differences in virologic outcomes among antiretroviral-naive clinical trial participants starting randomized ART and to investigate factors to explain the differences...
  40. pmc Ocular syphilis among HIV-infected individuals
    Jonathan Z Li
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Infect Dis 51:468-71. 2010
    ..5 years. In patients with HIV infection, clinicians should be vigilant for ocular syphilis despite normal cerebrospinal fluid measures and for syphilis reinfection...
  41. pmc Intimacy and sexual decision making: exploring the perspective of HIV positive women over 50
    Christina Psaros
    Department of Psychiatry, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    AIDS Patient Care STDS 26:755-60. 2012
    ..The themes and issues identified by this study may help guide sexual health-related interventions for older HIV-infected women...
  42. doi request reprint Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report
    Jatin M Vyas
    Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Infect Dis 45:1588-90. 2007
    ..Atovaquone-proguanil appears to have activity against babesiosis and should be studied as a potential therapy for patients with refractory babesiosis...
  43. ncbi request reprint BK virus-associated hemorrhagic cystitis in a Human Immunodeficiency Virus-infected patient
    Dan H Barouch
    Division of Infectious Diseases, Massachusetts General Hospital, and Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA, USA
    Clin Infect Dis 35:326-9. 2002
    ....
  44. doi request reprint Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro
    Kersten K Koelsch
    University of California, San Diego, USA
    J Infect Dis 197:411-9. 2008
    ..Recent studies report an association between HIV-1 DNA levels, disease progression, and treatment outcome. However, HIV-1 DNA exists as distinct molecular forms that are not distinguished by conventional assays...
  45. ncbi request reprint Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study
    Nancy R Reynolds
    Ohio State University, Columbus 43210, USA
    AIDS Behav 8:141-50. 2004
    ....
  46. ncbi request reprint GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype
    Carolynne Schwarze-Zander
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    J Infect Dis 194:410-9. 2006
    ..We therefore investigated (1) the prevalence and genotype of GBV-C in hepatitis C virus (HCV)/HIV-coinfected patients and (2) the impact of HCV treatment on GBV-C RNA clearance...
  47. pmc Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
    Patrick F Smith
    Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
    Antimicrob Agents Chemother 49:3558-61. 2005
    ..There were no significant differences in efavirenz pharmacokinetics...
  48. ncbi request reprint Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects
    Caroline M Behler
    Department of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143 1270, USA
    Clin Infect Dis 44:1375-83. 2007
    ....
  49. ncbi request reprint Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study
    Alison A Motsinger
    Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Pharmacogenet Genomics 16:837-45. 2006
    ..We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms...
  50. ncbi request reprint Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
    David W Haas
    Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Infect Dis 192:1931-42. 2005
    ..Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment...
  51. ncbi request reprint Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy
    Asha R Kallianpur
    Department of Medicine, Divisions of General Internal Medicine and Public Health, Nashville, TN, USA
    AIDS 20:1503-13. 2006
    ..Since iron deficiency is associated with some types of PN, and iron is essential for mitochondrial function, we tested the hypothesis that hemochromatosis (HFE) gene mutations influence susceptibility to NRTI-induced PN...
  52. ncbi request reprint Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial
    Nancy R Reynolds
    AIDS Clinical Trials Unit, Ohio State University, Columbus, OH, USA
    J Acquir Immune Defic Syndr 47:62-8. 2008
    ..To determine whether proactive telephone support improves adherence to antiretroviral therapy (ART) and clinical outcomes when compared to standard care...
  53. ncbi request reprint Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial
    Kathleen Mulligan
    Department of Medicine, Division of Endocrinology, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 41:590-7. 2006
    ..We examined intraindividual changes in dual-energy x-ray absorptiometry (DEXA) and anthropometry data over 64 weeks after initiation of antiretroviral therapy (ART)...
  54. ncbi request reprint Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study
    Todd Hulgan
    Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Acquir Immune Defic Syndr 42:450-4. 2006
    ..Mitochondria play a central role in regulating oxidant stress. We explored the relationships between oxidant stress and NRTI-induced peripheral neuropathy...

Research Grants2

  1. Bridging the Gap HIV Trials and Clinical Practice
    Gregory Robbins; Fiscal Year: 2007
    ..abstract_text> ..